Immunostimulatory role of mitochondrial DAMPs: alarming for pre-eclampsia?

American Journal of Reproductive Immunology

Volumn 76, Issue 5, 2016, Pages 341-347

  McCarthy, Cathal Michael ^a   Kenny, Louise Clare ^a  

^a Ireland   (Ireland)

Author keywords

damage associated molecular patterns; innate immune response; mitochondrial DNA; mitochondrial dysfunction; redox signals

Indexed keywords

BIOLOGICAL FACTOR; FORMYLPEPTIDE; MITOCHONDRIAL DAMAGE ASSOCIATED MOLECULAR PATTERN; MITOCHONDRIAL DNA; MITOCHONDRIAL N FORMYLPEPTIDE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CELL FUNCTION; CYTOKINE PRODUCTION; EUKARYOTIC CELL; HUMAN; IMMUNOSTIMULATION; INFLAMMATION; INNATE IMMUNITY; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PREECLAMPSIA; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW;

EID: 84990240712     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12526     Document Type: Review

References (63)

1. Pelletier M, Lepow TS, Billingham LK, Murphy MP, Siegel RM. New tricks from an old dog: mitochondrial redox signaling in cellular inflammation. Semin Immunol. 2012;24:384–392.
2. Malik AN, Czajka A. Is mitochondrial DNA content a potential biomarker of mitochondrial dysfunction? Mitochondrion. 2013;13:481–492.
3. Murphy Michael P. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1–13.
4. Li X, Fang PF, Mai J, Choi ET, Wang H, Yang X-f. Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers. J Hematol Oncol. 2013;6:1–9.
5. Malik AN, Shahni R, Rodriguez-de-Ledesma A, Laftah A, Cunningham P. Mitochondrial DNA as a non-invasive biomarker: accurate quantification using real time quantitative PCR without co-amplification of pseudogenes and dilution bias. Biochem Biophys Res Commun. 2011;412:1–7.
6. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045.
7. Sagan L. On the origin of mitosing cells. J Theor Biol. 1967;14:255–274.
8. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. 2012;48:158–167.
9. Wenceslau CF, McCarthy CG, Szasz T, Spitler K, Goulopoulou S, Webb RC. Mitochondrial damage-associated molecular patterns and vascular function. Eur Heart J. 2014;35:1172–1177.
10. He X, Qu F, Zhou F, et al. High leukocyte mtDNA content contributes to poor prognosis through ROS-mediated immunosuppression in hepatocellular carcinoma patients. Oncotarget. 2016;7:22834–22845.
11. Shen J, Wan J, Song R, Zhao H. Peripheral blood mitochondrial DNA copy number, length heteroplasmy and breast cancer risk: a replication study. Carcinogenesis. 2015;36:1307–1313.
12. Malik AN, Parsade CK, Ajaz S, et al. Altered circulating mitochondrial DNA and increased inflammation in patients with diabetic retinopathy. Diabetes Res Clin Pract. 2015;110:257–265.
13. Fetterman JL, Holbrook M, Westbrook DG, et al. Mitochondrial DNA damage and vascular function in patients with diabetes mellitus and atherosclerotic cardiovascular disease. Cardiovasc Diabetol. 2016;15:53.
14. Yu EP, Bennett MR. Mitochondrial DNA damage and atherosclerosis. Trends Endocrinol Metab. 2014;25:481–487.
15. Yu E, Calvert PA, Mercer JR, et al. Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans. Circulation. 2013;128:702–712.
16. Qiu C, Henver KH, Enquobahrie DA, Williams MA. A case-control study of maternal blood mitochondrial DNA copy number and preeclampsia risk. Int J Mol Epidemiol Genet. 2012;3:237–244.
17. Carp H. Mitochondrial N-formylmethionyl proteins as chemoattractants for neutrophils. J Exp Med. 1982;155:264–275.
18. Wenceslau CF, McCarthy CG, Goulopoulou S, Szasz T, NeSmith EG, Webb RC. Mitochondrial-derived N-formyl peptides: novel links between trauma, vascular collapse and sepsis. Med Hypotheses. 2013;81:532–535.
19. Iyer SS, He Q, Janczy JR, et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity. 2013;39:311–323.
20. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001;15:2922–2933.
21. Weinberg SE, Sena LA, Chandel NS. Mitochondria in the regulation of innate and adaptive immunity. Immunity. 2015;42:406–417.
22. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104–107.
23. Sun S, Sursal T, Adibnia Y, et al. Mitochondrial DAMPs increase endothelial permeability through neutrophil dependent and independent pathways. PLoS ONE. 2013;8:e59989.
24. Gupta AK, Hasler P, Holzgreve W, Gebhardt S, Hahn S. Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia. Hum Immunol. 2005;66:1146–1154.
25. McCarthy CG, Wenceslau CF, Goulopoulou S, et al. Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. Cardiovasc Res. 2015;107:119–130.
26. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. Nature. 2011;469:221–225.
27. Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821–832.
28. Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011;12:222–230.
29. Shimada K, Crother TR, Karlin J, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012;36:401–414.
30. Kaminski MM, Sauer SW, Klemke CD, et al. Mitochondrial reactive oxygen species control T cell activation by regulating IL-2 and IL-4 expression: mechanism of ciprofloxacin-mediated immunosuppression. J Immunol. 2010;184:4827–4841.
31. Yi JS, Holbrook BC, Michalek RD, Laniewski NG, Grayson JM. Electron transport complex I is required for CD8+ T cell function. J Immunol. 2006;177:852–862.
32. Murphy MP, Siegel RM. Mitochondrial ROS fire up T cell activation. Immunity. 2013;38:201–202.
33. Gemma C, Sookoian S, Alvarinas J, et al. Maternal pregestational BMI is associated with methylation of the PPARGC1A promoter in newborns. Obesity (Silver Spring). 2009;17:1032–1039.
34. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol. 2010;5:173–192.
35. Pennington KA, Schlitt JM, Jackson DL, Schulz LC, Schust DJ. Preeclampsia: multiple approaches for a multifactorial disease. Dis Model Mech. 2012;5:9–18.
36. Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response–a review. Placenta. 2003;24(Suppl. A):S21–S27.
37. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180(Pt 1):499–506.
38. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today. 1993;14:353–356.
39. Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010;63:534–543.
40. Sharma A, Satyam A, Sharma JB. Leptin, IL-10 and inflammatory markers (TNF-alpha, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women. Am J Reprod Immunol. 2007;58:21–30.
41. Southcombe J, Tannetta D, Redman C, Sargent I. The immunomodulatory role of syncytiotrophoblast microvesicles. PLoS ONE. 2011;6:e20245.
42. Zhong XY, Laivuori H, Livingston JC, et al. Elevation of both maternal and fetal extracellular circulating deoxyribonucleic acid concentrations in the plasma of pregnant women with preeclampsia. Am J Obstet Gynecol. 2001;184:414–419.
43. Bianchi DW. Circulating fetal DNA: its origin and diagnostic potential-a review. Placenta. 2004;25(Suppl. A):S93–S101.
44. Blair JD, Yuen RK, Lim BK, McFadden DE, von Dadelszen P, Robinson WP. Widespread DNA hypomethylation at gene enhancer regions in placentas associated with early-onset pre-eclampsia. Mol Hum Reprod. 2013;19:697–708.
45. Hahn S, Giaglis S, Buser A, Hoesli I, Lapaire O, Hasler P. Cell-free nucleic acids in (maternal) blood: any relevance to (reproductive) immunologists? J Reprod Immunol. 2014;104–105:26–31.
46. Scharfe-Nugent A, Corr SC, Carpenter SB, et al. TLR9 provokes inflammation in response to fetal DNA: mechanism for fetal loss in preterm birth and preeclampsia. J Immunol. 2012;188:5706–5712.
47. Coffman TM. Under pressure: the search for the essential mechanisms of hypertension. Nat Med. 2011;17:1402–1409.
48. Guzik TJ, Hoch NE, Brown KA, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204:2449–2460.
49. Mando C, De Palma C, Stampalija T, et al. Placental mitochondrial content and function in intrauterine growth restriction and preeclampsia. Am J Physiol Endocrinol Metab. 2014;306:E404–E413.
50. Pineda A, Verdin-Teran SL, Camacho A, Moreno-Fierros L. Expression of toll-like receptor TLR-2, TLR-3, TLR-4 and TLR-9 is increased in placentas from patients with preeclampsia. Arch Med Res. 2011;42:382–391.
51. Panda B, Panda A, Ueda I, et al. Dendritic cells in the circulation of women with preeclampsia demonstrate a pro-inflammatory bias secondary to dysregulation of TLR receptors. J Reprod Immunol. 2012;94:210–215.
52. Goulopoulou S, Matsumoto T, Bomfim GF, Webb RC. Toll-like receptor 9 activation: a novel mechanism linking placenta-derived mitochondrial DNA and vascular dysfunction in pre-eclampsia. Clin Sci (Lond). 2012;123:429–435.
53. Pradervand PA, Clerc S, Frantz J, et al. High mobility group box 1 protein (HMGB-1): a pathogenic role in preeclampsia? Placenta. 2014;35:784–786.
54. Artunc-Ulkumen B, Guvenc Y, Goker A, Gozukara C. Maternal Serum S100-B, PAPP-A and IL-6 levels in severe preeclampsia. Arch Gynecol Obstet. 2015;292:97–102.
55. Peracoli JC, Bannwart-Castro CF, Romao M, et al. High levels of heat shock protein 70 are associated with pro-inflammatory cytokines and may differentiate early- from late-onset preeclampsia. J Reprod Immunol. 2013;100:129–134.
56. Colleoni F, Lattuada D, Garretto A, et al. Maternal blood mitochondrial DNA content during normal and intrauterine growth restricted (IUGR) pregnancy. Am J Obstet Gynecol. 2010;203:365 e1-6.
57. Velez DR, Menon R, Simhan H, Fortunato S, Canter JA, Williams SM. Mitochondrial DNA variant A4917G, smoking and spontaneous preterm birth. Mitochondrion. 2008;8:130–135.
58. Baumbusch MA, Buhimschi CS, Oliver EA, et al. High Mobility Group-Box 1 (HMGB1) levels are increased in amniotic fluid of women with intra-amniotic inflammation-determined preterm birth, and the source may be the damaged fetal membranes. Cytokine. 2016;81:82–87.
59. Romero R, Miranda J, Chaiworapongsa T, et al. Prevalence and clinical significance of sterile intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Reprod Immunol. 2014;72:458–474.
60. Florio P, Marinoni E, Di Iorio R, et al. Urinary S100B protein concentrations are increased in intrauterine growth-retarded newborns. Pediatrics. 2006;118:e747–e754.
61. Gazzolo D, Marinoni E, Di Iorio R, et al. High maternal blood S100B concentrations in pregnancies complicated by intrauterine growth restriction and intraventricular hemorrhage. Clin Chem. 2006;52:819–826.
62. McCarthy C, Kenny LC. [15-OR]: Elucidation of a role for mitochondrial superoxide in modulating plasma mediator-induced endothelial dysfunction. Pregnancy Hypertens. 2015;5:8.
63. Kenny LC, Broadhurst DI, Dunn W, et al. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension. 2010;56:741–749.